Application of Histamine Receptors H2R, H3R, and H4R, but Not H1R, in Dermatology

September 2014 in “ International Journal of Dermatology and Venereology ”

Linfang Yang, Yuping Cao, Ping Ma

histamine receptors H2R H3R H4R H1R H2 receptor antagonists H1 receptor antagonists chronic urticaria skin warts herpes zoster simplex herpes androgenic alopecia acne H3 receptor ligands H4 receptor antagonists anti-inflammatory anti-itching H2 receptor blockers H1 receptor blockers chronic hives shingles cold sores male pattern baldness H3 receptor drugs H4 receptor blockers

Studysummary This review explores the roles of histamine receptors H2R, H3R, and H4R in treating various dermatoses but reports no new clinical outcomes.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

Read the full study on rs.yiigle.com →

Discuss this study in the Community →

Similar research 5

Use of H-1 Antihistamine in Dermatology: More Than Itch and Urticaria Control: A Systematic Review Dermatology and Therapy · 2021
New Approaches to the Physiology of Histamine Physiological Reviews · 1968
TRPV3 as a Therapeutic Target for Itch Journal of Investigative Dermatology · 2012
Mast Cell-5-HT-HTR2A Axis Involvement in Chronic Itch Induced by SADBE Molecular Pain · 2025
Characterising Neurotransmitter Signalling in Human Skin and Hair Follicles Journal of Investigative Dermatology · 2024

Related Community Posts Join

6 / 1000+ results

community Hope Medicine's HMI-115 could be out in 2027 per Company Founder

34 upvotes 1 year ago

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news

13 upvotes 9 months ago

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

community Histamine intolerance and topical treatments

in Treatments 66 upvotes 1 year ago

The user experiences histamine intolerance with alcohol-based hair loss treatments like Rogaine foam and seeks alternatives. Suggestions include alcohol-free and PPG-free topical minoxidil or finasteride, and trying Spectral products with different solvents.

community do hyper responders just have better absorption in there gut?

4 upvotes 3 years ago

The conversation discusses the impact of H. pylori on nutrient absorption, specifically iron and B12. It also mentions checking serum DHT levels as a potential solution.

community Is hmi 115 the cure? Or is it 🧢 just like cosmeRNA, brezula, pyrilutamide, and other 📞 ies

15 upvotes 2 years ago

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

community Has there been any update or progress on the 3-alpha hydroxysteroid dehydrogenase hypothesis?

13 upvotes 2 months ago

The conversation discusses the hypothesis that a lack of the enzyme 3-alpha hydroxysteroid dehydrogenase (3α-HSD) on the scalp may contribute to hair loss by allowing DHT to accumulate. Despite interest in this theory, no recent research has been conducted, and current treatments like finasteride and minoxidil remain the most supported options.